Companies: 10,795·Total market cap: $144.5T
Aeolus Pharmaceuticals, Inc.

Aeolus Pharmaceuticals, Inc.

AOLSOTCHealthcare● Active
$0.00
+$0.00(+0.00%)
Market Cap$15209
P/E Ratio
52W High$0.0001
52W Low$0.0001

Aeolus Pharmaceuticals, Inc. (AOLS) Revenue

Annual & quarterly revenue history · segment & region breakdown

AOLS · revenue · updated Jun 9, 2026

Core revenue metrics

Aeolus Pharmaceuticals, Inc. trailing twelve-month (TTM) revenue is $0.00B, an increase of 0.00% year-over-year from — in FY.

TTM revenue
$0.00B
4-quarter sum · USD
YoY growth
+0.00%
vs FY
Price / sales
0.02×
mktCap ÷ TTM rev
Revenue per day
$0M
Est. TTM ÷ 365
Revenue / employee
$193K
4 employees
FY
FY
5Y CAGR
Fiscal year end
Dec 31
Currency
USD · GAAP
Filing
10-K / 10-Q
Source: FMP · Aeolus Pharmaceuticals, Inc. SEC filings · GAAPUpdated: 2026-06-09

Revenue trend

· Annual
YoY revenue growth %
revenue trend · revenue chart · revenue by year · revenue history

Revenue history

Fiscal year endRevenueChangeGrowth
AOLS revenue by year · AOLS revenue history · AOLS annual revenue data

About Revenue & Reporting

Revenue (also called sales, net sales, or turnover) is the total income Aeolus Pharmaceuticals, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.

Aeolus Pharmaceuticals, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.

Data sourced from Aeolus Pharmaceuticals, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.

Figures tie to SEC 10-K/10-Q and FMP income-statement endpoints where noted.

Frequently asked questions

AOLS revenue · 4 questions

AOLS's trailing twelve-month (TTM) revenue is $0.00B. That is an increase of 0.00% year-over-year from — in FY.

AOLS revenueAOLS annual revenuewhat is AOLS revenueAOLS TTM revenue

Source: FMP · Aeolus Pharmaceuticals, Inc. SEC filings · GAAP · Aeolus Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026